

NIH Institutional Biosafety Committee Minutes National Institute of Environmental Health Sciences

Thursday, Aug 14, 2025

3:30 PM – 4:30 PM

Virtual via Teams

Members Present:

Quorum Met: Yes

☒	Francesco Demayo	Chair	☒	Huanchen Wang	Cell & Molecular Expert
☒	Christopher McGee	Biosafety Officer	☐	Lawrence Kirschner	Clinical Expert
☒	David Kurtz	Animal Expert	☐	Stephen Novak	Ex Officio
☐	Robert Petrovich	Protein Expression Expert	☐	John McLamb	Radiological Expert
☒	Justin Kosak	Lab Representative	☒	Jacqueline Hamilton	Community Representative
☒	Shih-Heng Chen	Virology Expert	☒	Troy Weaver	Community Representative
☒	Andrew Newell	Toxicology Expert			

Guests Present:

Althea Treacy, BMB Branch Chief, NIH

Announcements & Call to Order

- I. Meeting called to order by Francesco Demayo at 3:32pm.
- II. The IBC Chair reminded all present members to identify any conflicts of interest as each registration is reviewed.

Review of Past IBC Meeting Minutes

- I. Jul 10, 2025 Minutes
 - a. The Jul 2025 minutes were unanimously approved as written

New Committee Business

- I. BSO or IBC lead reviewer preliminary registration approvals since the previous meeting.
 - a. None

II. Registrations for Committee review

- a. Registrations for committee review:

Registration Number, PI: B-1987, Lawrence Kirschner

- i. Reviewers: Huanchen Wang
- ii. Review Summary: The investigator seeks to create mouse embryonic fibroblast and human thyroid carcinoma cell lines lacking targeted metabolic genes to model tumorigenesis associated with mutations in the respective genes of interest. CRISPR will be used to generate direct or indirect null alleles. Conditional knock-out alleles will be treated with lenti-cre-reporter to generate

indirect null alleles. Cells will undergo transcriptomic, metabolomic and DNA methylation analysis. Identified hazards are, use of replication incompetent 2nd generation lenti-cre constructs and established human cells.

- iii. Committee Discussion: Minimum BSL-2/3. Minimum PPE includes splash resistant closed front gown, double gloves, and safety glasses. Work shall be performed in a Class II BSC. Disinfect with a 1:10 dilution of bleach made fresh at least weekly. Dispose all solid biohazard waste in an orange biohazard bag. All liquid biohazard waste must be collected and submitted for pick up through EHSA.
- iv. Training: All personnel listed on the biopermit are required to maintain annual biosafety refresher, annual bloodborne pathogen, and biannual laboratory safety training. All personnel working directly with lentiviral vectors must receive hands-on training with the viral vector core before working independently.
- v. Animal studies proposed: No. Mouse embryonic fibroblast cell lines are being received from an extramural collaborator.
- vi. The committee discussed the dual-use and PEPP potential of these experiments. The committee agreed that there were no dual-use or PEPP concerns with the proposal.
- vii. Public comment: Non-affiliated IBC members did not express any community concerns in relation to this biological permit. No additional public comment have been made in relation to this permit.
- viii. Work is approved at: BSL-2/3.
- ix. Relevant sections of the NIH Guidelines: III-D-3-a
- x. A motion was made and seconded to approve the permit
- xi. The committee unanimously approved.
 - 1. Conflicts of interest: IBC member, Lawrence Kirschner, was not in attendance during the committee meeting.
 - 2. Votes for: 9 Votes against: 0 Abstained: 0

- I. Committee Review of Inactivation Procedures
 - a. None

- II. Standard Operating Procedures/Plans
 - a. None

- III. Serious Adverse Events in Clinical Trials reviewed by the Committee
 - a. None

Reports

- I. Biosafety Officer Report –
 - a. Reported mouse bite incident during handling. No biohazardous agents were in use during the incident.

Around the Room/Committee Discussion

- I. None

Adjournment

- I. Meeting adjourned by Francesco Demayo at 3:52 pm

Next Meeting

- I. Sept 11th, 2025, virtual via Teams